These inhibitors were shown to block the catalytic activity at the C271 site in recombinant NSUN2 and disrupt the NSUN2-tRNA interaction in cancer cells, resulting in decreased tRNA m5C content and suppression of cancer progression [139]. The gene discussed is NSUN2; the disease is cancer.